Merck & Co., Inc. MRK

148.78 0.80 0.54% as of 25 Sep
Market cap
$365.4B
P/E
119×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Merck & Co., Inc. (MRK) P/B ratio

As of 25 September 2026, Merck & Co., Inc. (MRK) trades at a P/B ratio of 8.8×. Over the past ten years it has ranged from 2.8× (September 2015) to 9.2× (August 2026); the current reading is higher than 99% of that period. That is above the Drug Manufacturers General industry median of 5.0× and above the Healthcare sector median of 2.5×.

P/B ratio, daily

Annual

Period P/B ratio Change
FY2025 5.0× (7.93%)
FY2024 5.4× (28.84%)
FY2023 7.6× 24.94%
FY2022 6.1× 20.55%
FY2021 5.1× (34.80%)
FY2020 7.8× (9.20%)
FY2019 8.6× 18.48%
FY2018 7.2× 70.54%
FY2017 4.2× 7.57%
FY2016 3.9× 24.24%

Quarterly

Period P/B ratio Change
Jun 2026 7.6× 16.77%
Mar 2026 6.5× 29.45%
Dec 2025 5.0× 23.97%
Sep 2025 4.0× (0.39%)
42 more quarters

Against its own ten years

Low 2.8× High 9.2×
Ten-year median 5.6×
Current reading's percentile 99

P/B ratio against peers

Company P/B ratio
ABBV AbbVie Inc. compare n/m
PFE Pfizer Inc. compare 1.9×
NVO Novo Nordisk A/S compare 5.0×
AZN AstraZeneca PLC compare 5.1×
NVS Novartis AG compare 6.6×
JNJ Johnson & Johnson compare 7.7×
MRK Merck & Co., Inc. 8.8×
GILD Gilead Sciences, Inc. compare 16.0×
AMGN Amgen Inc. compare 19.2×
Drug Manufacturers General industry median 5.0×
Healthcare sector median 2.5×
Market median 1.8×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on MRK